# DMTA Orchestration Agent - Workflow Story

## Complete Chat Conversation Flow

This document describes the end-to-end conversation flow from project planning to finding optimized candidate molecules, based on the active learning approach from the AWS Healthcare AI/ML sample notebooks.

### Initial Project Setup

**User**: "Please create a project plan to optimize Cablivi (Caplacizumab) for improved vWF binding affinity"

**Agent Response**:
```
DMTA Project Plan Created: Cablivi (Caplacizumab) Optimization

Knowledge Base Search Results:
- Found 15 similar nanobody optimization project plans
- Relevant precedent: Anti-TNF nanobody (Adalimumab biosimilar) optimization achieved 10x affinity improvement
- Key insights: CDR3 loop modifications most effective for binding enhancement
- Historical success rate: 85% of projects achieved target binding within 3-4 cycles

Project Plan Document Generated and Saved to S3:
- Document: projects/cablivi-opt-001/plans/project_plan.md
- S3 URL: https://dmta-experimental-data.s3.amazonaws.com/projects/cablivi-opt-001/plans/project_plan.md

Target: von Willebrand Factor (vWF) A1 domain binding optimization
Optimization Objective: Improve binding affinity (target KD < 1 nM)
Strategy: Active Learning with Gaussian Process modeling
Acquisition Functions: Expected Improvement (EI) and Upper Confidence Bound (UCB)

Initial Setup:
- Starting compound: Caplacizumab (ALX-0081) - current KD ~3.2 nM
- Initial training set: 12 Nanobody variants with known vWF binding data
- Target cycles: 4-6 iterations (based on similar projects)
- Convergence criteria: KD < 1 nM or improvement < 3% over 2 cycles

Timeline: 8-10 weeks (2 weeks per cycle)
Resources: Nanobody engineering + expression + SPR binding assays

Recommendations from Knowledge Base:
- Prioritize CDR3 mutations (S101, Y100, T102 positions)
- Monitor expression levels to avoid stability issues
- Use SPR kinetics analysis for accurate KD determination

Plan phase completed. Would you like to start the Design phase for Cycle 1?
```

### Cycle 1: Design Phase

**User**: "Start the Design phase for Cycle 1"

**Agent Response**:
```
DESIGN Phase - Cycle 1 Started

- Gaussian Process model trained on 12 initial Nanobody variants
- Applied Expected Improvement acquisition function
- Identified 8 promising Caplacizumab variants for engineering

Selected Nanobody Variants for Cycle 1:
1. Variant N1-001: CDR3 mutation S101A, Predicted KD = 2.1 nM (EI score: 0.89)
2. Variant N1-002: CDR1 mutation G26D, Predicted KD = 2.8 nM (EI score: 0.82)
3. Variant N1-003: CDR2 mutation Y58F, Predicted KD = 2.4 nM (EI score: 0.78)
4. Variant N1-004: CDR3 mutation T102S, Predicted KD = 2.9 nM (EI score: 0.74)
5. Variant N1-005: Framework mutation A84V, Predicted KD = 3.1 nM (EI score: 0.71)
6. Variant N1-006: CDR1 mutation S31T, Predicted KD = 2.6 nM (EI score: 0.68)
7. Variant N1-007: CDR2 mutation D54N, Predicted KD = 3.4 nM (EI score: 0.65)
8. Variant N1-008: CDR3 mutation R103K, Predicted KD = 2.3 nM (EI score: 0.62)

Design phase completed. Would you like to start the Make phase?
```

### Cycle 1: Make Phase

**User**: "Start the Make phase"

**Agent Response**:
```
MAKE Phase - Cycle 1 Started

Nanobody Expression Progress (FactorX Simulation):
- Variant N1-001: Expression completed, Yield: 12.4 mg/L, Purity: 98.1%
- Variant N1-002: Expression completed, Yield: 10.8 mg/L, Purity: 97.3%
- Variant N1-003: Expression completed, Yield: 13.2 mg/L, Purity: 98.7%
- Variant N1-004: Expression completed, Yield: 11.5 mg/L, Purity: 96.9%
- Variant N1-005: Expression completed, Yield: 9.7 mg/L, Purity: 97.8%
- Variant N1-006: Expression completed, Yield: 12.1 mg/L, Purity: 98.2%
- Variant N1-007: Expression completed, Yield: 8.9 mg/L, Purity: 96.4%
- Variant N1-008: Expression completed, Yield: 11.8 mg/L, Purity: 97.6%

Expression Summary:
- Success rate: 100% (8/8 variants)
- Average yield: 11.3 mg/L
- Average purity: 97.6%
- All variants purified and ready for binding assays

Make phase completed. Would you like to start the Test phase?
```

### Cycle 1: Test Phase

**User**: "Start the Test phase"

**Agent Response**:
```
TEST Phase - Cycle 1 Started

Surface Plasmon Resonance (SPR) Binding Assays (FactorX Generated Data):
- Variant N1-001: vWF A1 binding assay completed
- Variant N1-002: vWF A1 binding assay completed
- Variant N1-003: vWF A1 binding assay completed
- Variant N1-004: vWF A1 binding assay completed
- Variant N1-005: vWF A1 binding assay completed
- Variant N1-006: vWF A1 binding assay completed
- Variant N1-007: vWF A1 binding assay completed
- Variant N1-008: vWF A1 binding assay completed

Assay Summary:
- All 8 variants tested successfully
- KD values determined via SPR kinetics
- Binding curves analyzed
- Quality control passed
- Results ready for analysis

Test phase completed. Would you like to start the Analysis phase?
```

### Cycle 1: Analysis Phase

**User**: "Start the Analysis phase"

**Agent Response**:
```
DMTA Cycle 1 - Results Analysis

ANALYZE Phase:
Experimental Results (FactorX Generated):
- N1-001: KD = 1.8 nM (vs predicted 2.1 nM) - Significant improvement!
- N1-002: KD = 3.1 nM (vs predicted 2.8 nM)
- N1-003: KD = 2.2 nM (vs predicted 2.4 nM)
- N1-004: KD = 3.4 nM (vs predicted 2.9 nM)
- N1-005: KD = 3.8 nM (vs predicted 3.1 nM)
- N1-006: KD = 2.5 nM (vs predicted 2.6 nM)
- N1-007: KD = 4.1 nM (vs predicted 3.4 nM)
- N1-008: KD = 2.0 nM (vs predicted 2.3 nM) â­ SECOND BEST

Model Performance:
- RÂ² correlation: 0.74 (good predictive power)
- Best variant: N1-001 (KD = 1.8 nM) - 44% improvement from parent!
- Model updated with 8 new data points (total: 20 variants)

Cycle 1 Summary:
âœ… Significant progress: N1-001 with KD = 1.8 nM (vs 3.2 nM parent)
âœ… Model accuracy improved with new data
âœ… SAR insights: CDR3 S101A mutation enhances vWF A1 binding

Recommendation: Continue to Cycle 2 to achieve sub-1 nM target and explore N1-001 neighborhood.
```

### Cycle 2: Design Phase

**User**: "Start the Design phase for Cycle 2"

**Agent Response**:
```
DESIGN Phase - Cycle 2 Started

- Updated Gaussian Process model with Cycle 1 results
- Applied Upper Confidence Bound (UCB) acquisition function for exploration
- Focus on N1-001 (S101A) neighborhood and complementary CDR mutations

Selected Nanobody Variants for Cycle 2:
1. Variant N2-001: S101A + Y58W double mutation (Predicted KD = 1.2 nM)
2. Variant N2-002: S101A + G26E double mutation (Predicted KD = 1.4 nM)
3. Variant N2-003: S101A + T102N double mutation (Predicted KD = 1.1 nM)
4. Variant N2-004: S101A + R103H double mutation (Predicted KD = 1.3 nM)
5. Variant N2-005: S101A + S31N double mutation (Predicted KD = 1.6 nM)
6. Variant N2-006: S101A + A84T framework mutation (Predicted KD = 1.5 nM)
7. Variant N2-007: S101A + D54E CDR2 mutation (Predicted KD = 1.7 nM)
8. Variant N2-008: S101A + Y100F adjacent mutation (Predicted KD = 1.0 nM)

Design phase completed. Would you like to start the Make phase for Cycle 2?
```

### Cycle 2: Make Phase

**User**: "Start the Make phase for Cycle 2"

**Agent Response**:
```
MAKE Phase - Cycle 2 Started

Synthesis Progress (FactorX Simulation):
- Compound C2-001: Synthesis completed, Purity: 97.1%
- Compound C2-002: Synthesis completed, Purity: 95.8%
- Compound C2-003: Synthesis completed, Purity: 96.4%
- Compound C2-004: Synthesis completed, Purity: 94.9%
- Compound C2-005: Synthesis completed, Purity: 96.2%
- Compound C2-006: Synthesis completed, Purity: 95.3%
- Compound C2-007: Synthesis completed, Purity: 97.0%
- Compound C2-008: Synthesis completed, Purity: 96.7%

Synthesis Summary:
- Success rate: 100% (8/8 compounds)
- Average purity: 96.2%
- All compounds ready for testing

Make phase completed. Would you like to start the Test phase for Cycle 2?
```

### Cycle 2: Test Phase

**User**: "Start the Test phase for Cycle 2"

**Agent Response**:
```
TEST Phase - Cycle 2 Started

Biochemical IC50 Assays (FactorX Generated Data):
- All 8 compounds tested successfully
- IC50 values determined
- Quality control passed

Test phase completed. Would you like to start the Analysis phase for Cycle 2?
```

### Cycle 2: Analysis Phase

**User**: "Start the Analysis phase for Cycle 2"

**Agent Response**:
```
ANALYZE Phase - Cycle 2 Results

Experimental Results (FactorX Generated):
- N2-001: KD = 1.1 nM (vs predicted 1.2 nM) - Excellent!
- N2-002: KD = 1.6 nM (vs predicted 1.4 nM)
- N2-003: KD = 0.9 nM (vs predicted 1.1 nM) â­ TARGET ACHIEVED!
- N2-004: KD = 1.4 nM (vs predicted 1.3 nM)
- N2-005: KD = 1.8 nM (vs predicted 1.6 nM)
- N2-006: KD = 1.7 nM (vs predicted 1.5 nM)
- N2-007: KD = 2.0 nM (vs predicted 1.7 nM)
- N2-008: KD = 0.8 nM (vs predicted 1.0 nM) â­ NEW BEST!

Model Performance:
- RÂ² correlation: 0.83 (excellent predictive power)
- Best variant: N2-008 (KD = 0.8 nM) - TARGET EXCEEDED!
- Model updated with 8 new data points (total: 28 variants)

Outstanding Results! Multiple variants now achieve sub-1 nM binding!
Analysis phase completed. Would you like to start Cycle 3 Design phase?
```

### Cycle 3: Design Phase

**User**: "Start the Design phase for Cycle 3"

**Agent Response**:
```
DESIGN Phase - Cycle 3 Started

- Model now trained on 28 variants with high confidence
- Applied hybrid EI/UCB strategy focusing on N2-008 (S101A+Y100F) neighborhood
- Exploring fine-tuning modifications for sub-0.5 nM binding

Selected Nanobody Variants for Cycle 3:
1. Variant N3-001: S101A+Y100F+G26D triple mutation (Predicted KD = 0.6 nM)
2. Variant N3-002: S101A+Y100F+T102S triple mutation (Predicted KD = 0.7 nM)
3. Variant N3-003: S101A+Y100F+S31T triple mutation (Predicted KD = 0.5 nM)
4. Variant N3-004: S101A+Y100F+R103K triple mutation (Predicted KD = 0.6 nM)
5. Variant N3-005: S101A+Y100F+D54N triple mutation (Predicted KD = 0.8 nM)
6. Variant N3-006: S101A+Y100F+A84V framework mutation (Predicted KD = 0.7 nM)
7. Variant N3-007: S101A+Y100W+T102N alternative (Predicted KD = 0.9 nM)
8. Variant N3-008: S101A+Y100H conservative mutation (Predicted KD = 0.4 nM)

Design phase completed. Would you like to start the Make phase for Cycle 3?
```

### Cycle 3: Make Phase

**User**: "Start the Make phase for Cycle 3"

**Agent Response**:
```
MAKE Phase - Cycle 3 Started

Synthesis Progress (FactorX Simulation):
- Compound C3-001: Synthesis completed, Purity: 98.1%
- Compound C3-002: Synthesis completed, Purity: 97.3%
- Compound C3-003: Synthesis completed, Purity: 96.8%
- Compound C3-004: Synthesis completed, Purity: 97.5%
- Compound C3-005: Synthesis completed, Purity: 95.9%
- Compound C3-006: Synthesis completed, Purity: 96.4%
- Compound C3-007: Synthesis completed, Purity: 94.7%
- Compound C3-008: Synthesis completed, Purity: 97.1%

Synthesis Summary:
- Success rate: 100% (8/8 compounds)
- Average purity: 96.7%
- Highest purity achieved in project

Make phase completed. Would you like to start the Test phase for Cycle 3?
```

### Cycle 3: Test Phase

**User**: "Start the Test phase for Cycle 3"

**Agent Response**:
```
TEST Phase - Cycle 3 Started

Biochemical IC50 Assays (FactorX Generated Data):
- All 8 compounds tested successfully
- IC50 values determined
- Quality control passed
- Final optimization data ready

Test phase completed. Would you like to start the Analysis phase for Cycle 3?
```

### Cycle 3: Final Analysis

**User**: "Start the Analysis phase for Cycle 3"

**Agent Response**:
```
ANALYZE Phase - Cycle 3 Final Results

Experimental Results (FactorX Generated):
- N3-001: KD = 0.52 nM (vs predicted 0.6 nM)
- N3-002: KD = 0.68 nM (vs predicted 0.7 nM)
- N3-003: KD = 0.41 nM (vs predicted 0.5 nM) â­ EXCELLENT!
- N3-004: KD = 0.59 nM (vs predicted 0.6 nM)
- N3-005: KD = 0.74 nM (vs predicted 0.8 nM)
- N3-006: KD = 0.63 nM (vs predicted 0.7 nM)
- N3-007: KD = 0.85 nM (vs predicted 0.9 nM)
- N3-008: KD = 0.35 nM (vs predicted 0.4 nM) â­ OPTIMAL CANDIDATE!

Model Convergence Analysis:
- Improvement over last cycle: <2% (convergence criteria met)
- Model RÂ²: 0.91 (outstanding predictive power)
- Total variants evaluated: 36

OPTIMIZATION SUCCESS! 
ðŸŽ¯ Optimal candidate found: N3-008 with KD = 0.35 nM
ðŸ“ˆ 900% improvement from parent Caplacizumab (3.2 nM â†’ 0.35 nM)
ðŸ”¬ Ready for preclinical development and stability studies

Key Mutations in Optimal Variant N3-008:
- CDR3: S101A (primary binding enhancement)
- CDR3: Y100H (complementary binding optimization)
- Predicted to maintain Caplacizumab's excellent safety profile

Analysis phase completed. Cablivi optimization achieved!
```

### Project Completion

**User**: "Summarize the complete Cablivi optimization project"

**Agent Response**:
```
Cablivi (Caplacizumab) Optimization Project - COMPLETED âœ…

PROJECT SUMMARY:
Duration: 3 cycles (6 weeks)
Total nanobody variants evaluated: 36
Success rate: 100% expression, 100% binding assays

OPTIMIZATION TRAJECTORY:
- Initial target: KD < 1 nM (vs parent 3.2 nM)
- Cycle 1 best: N1-001 = 1.8 nM (44% improvement)
- Cycle 2 best: N2-008 = 0.8 nM (target achieved)
- Cycle 3 best: N3-008 = 0.35 nM (900% improvement) â­

FINAL OPTIMIZED CANDIDATES:
1. N3-008: KD = 0.35 nM (S101A+Y100H) - PRIMARY CANDIDATE
2. N3-003: KD = 0.41 nM (S101A+Y100F+S31T) - BACKUP CANDIDATE
3. N3-001: KD = 0.52 nM (S101A+Y100F+G26D) - ALTERNATIVE

KEY SUCCESS FACTORS:
âœ… Active learning approach with Gaussian Process modeling
âœ… Strategic CDR3 optimization (S101A foundation)
âœ… Complementary mutation identification (Y100H)
âœ… Efficient nanobody engineering workflow
âœ… Sub-nanomolar binding affinity achieved

NEXT STEPS:
- Proceed with N3-008 for preclinical development
- Conduct stability and aggregation studies
- Evaluate pharmacokinetic properties
- Assess immunogenicity risk
- Scale-up production for clinical studies

Project Status: OPTIMIZATION COMPLETE - READY FOR PRECLINICAL DEVELOPMENT
```

## Key Workflow Components

### 1. Active Learning Strategy
- Gaussian Process modeling for binding affinity prediction
- Expected Improvement (EI) for exploitation of promising regions
- Upper Confidence Bound (UCB) for exploration of uncertain areas
- Iterative model updating with SPR binding data

### 2. FactorX Dummy Data Generation
- Realistic KD values with appropriate experimental variance
- Correlation with predicted values (RÂ² = 0.7-0.9)
- Progressive improvement across cycles (3.2 nM â†’ 0.35 nM)
- Convergence behavior matching real nanobody optimization

### 3. Conversation Flow Pattern
- **Planning**: Cablivi optimization setup and vWF binding strategy
- **Design**: Nanobody variant selection using acquisition functions
- **Make/Test**: FactorX simulation of expression and SPR assays
- **Analyze**: Binding results interpretation and next cycle planning
- **Iterate**: Repeat until sub-nanomolar binding achieved

### 4. Success Metrics
- Target achievement (KD < 1 nM, achieved 0.35 nM)
- Model accuracy improvement (RÂ² progression: 0.74 â†’ 0.91)
- Convergence detection (<2% improvement in final cycle)
- Multiple sub-nanomolar candidates identified

This workflow demonstrates the complete DMTA orchestration from initial Cablivi optimization planning through successful nanobody engineering, using active learning principles to efficiently navigate protein sequence space and achieve sub-nanomolar vWF binding affinity.